Clinical Trial Update: GEfitinib Plus viNOrelbine in Advanced EGFR Mutated NSCLC. GENOA Trial [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating gefitinib plus vinorelbine in advanced EGFR-mutated non-small cell lung cancer (GENOA trial) with status currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Gefitinib (Iressa) (gefitinib)
• Vinorelbine (Navelbine) (vinorelbine tartrate)

Snippet

Sponsor: IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: UNKNOWN